ImmunityBio Stock Jumps on Expanded FDA Approval for Cancer Drug Anktiva

Key Facts

1ImmunityBio stock jumped over 5% following expanded FDA approval for its treatment.

2The expanded approval is for the drug Anktiva in treating NMIBC bladder cancer.

ImmunityBio stock jumped over 5% following expanded FDA approval for its treatment. Benzinga reported that the expanded approval is for the drug Anktiva, which is used in treating NMIBC bladder cancer.

IBRX closed at $9.8 on October 13, 2026, after reaching a day high of $10.06 and a low of $9.56. This regulatory milestone serves as a fundamental catalyst for the biotech firm, directly impacting its potential market size and therapeutic reach.